The evolutionarily conserved long non‐coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and …
RL Mather, A Parolia, SE Carson… - Molecular …, 2021 - Wiley Online Library
Metastatic neuroendocrine prostate cancer (NEPC) is a highly aggressive disease, whose
incidence is rising. Long noncoding RNAs (lncRNAs) represent a large family of disease …
incidence is rising. Long noncoding RNAs (lncRNAs) represent a large family of disease …
Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer
E Jachetti, V Cancila, A Rigoni, L Bongiovanni… - Cancer immunology …, 2018 - AACR
Immunotherapy, including the use of checkpoint inhibitors, is a potent therapeutic approach
for some cancers, but has limited success with prostate tumors, in which immune …
for some cancers, but has limited success with prostate tumors, in which immune …
[HTML][HTML] The Multifaceted Role of Osteopontin in Prostate Pathologies
SV Silver, P Popovics - Biomedicines, 2023 - mdpi.com
The prostate gland, located beneath the bladder and surrounding the proximal urethra in
men, plays a vital role in reproductive physiology and sexual health. Despite its importance …
men, plays a vital role in reproductive physiology and sexual health. Despite its importance …
[HTML][HTML] Gene expression signature predictive of neuroendocrine transformation in prostate adenocarcinoma
Neuroendocrine prostate cancer (NEPC) can arise de novo, but much more commonly
occurs as a consequence of a selective pressure from androgen deprivation therapy or …
occurs as a consequence of a selective pressure from androgen deprivation therapy or …
[HTML][HTML] Intracellular osteopontin promotes the release of TNFα by mast cells to restrain neuroendocrine prostate cancer
R Sulsenti, GB Scialpi, B Frossi, L Botti, R Ferri… - Cancer Immunology …, 2024 - AACR
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer that
emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in …
emerges as tumors become resistant to hormone therapies or, rarely, arises de novo in …
[HTML][HTML] Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression
Neuroendocrine prostate cancer (NEPC) typically implies severe lethality and limited
treatment options. The precise identification of NEPC cells holds paramount significance for …
treatment options. The precise identification of NEPC cells holds paramount significance for …
[HTML][HTML] Repurposing of the antiepileptic drug levetiracetam to restrain neuroendocrine prostate cancer and inhibit mast cell support to adenocarcinoma
A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …
neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of …
Imatinib spares cKit-expressing prostate neuroendocrine tumors, whereas kills seminal vesicle epithelial–stromal tumors by targeting PDGFR-β
E Jachetti, A Rigoni, L Bongiovanni, I Arioli, L Botti… - Molecular cancer …, 2017 - AACR
Prostate cancer is a leading cause of cancer-related death in males worldwide. Indeed,
advanced and metastatic disease characterized by androgen resistance and often …
advanced and metastatic disease characterized by androgen resistance and often …
[HTML][HTML] Increased Circulating Osteopontin Levels Promote Primary Tumour Growth, but Do Not Induce Metastasis in Melanoma
R Saup, N Nair, J Shen, A Schmaus, W Thiele… - Biomedicines, 2023 - mdpi.com
Osteopontin (OPN) is a phosphoprotein with diverse functions in various physiological and
pathological processes. OPN expression is increased in multiple cancers, and OPN within …
pathological processes. OPN expression is increased in multiple cancers, and OPN within …
Innovative therapy, monoclonal antibodies and beyond
Abstract The seventh Edition of “Innovative Therapy, Monoclonal Antibodies and Beyond”
Meeting took place in Milan, Italy, on January 27, 2017. The two sessions of the meeting …
Meeting took place in Milan, Italy, on January 27, 2017. The two sessions of the meeting …